A unique range of integrated early stage development services to support biopharmaceutical drug development.

Solutions through experience

This extensive suite of contract testing and development services combines BioOutsource and Cellca’s expertise in cell line development, bioanalytical testing, cell bank manufacturing and biosafety contract testing to support customers from cell line development, through product manufacture and release. Broadening Sartorius Stedim Biotech’s portfolio of products, technologies and services and enabling a comprehensive “Total Solution” to support our clients’ drug development activities.

Benefit from the combined experience of Cellca, BioOutsource to efficiently advance your drug candidates quickly from early stage development through to commercialisation.

Accelerated drug development

Based on its unparalleled global experience working to support biological drug development, BioOutsource and Cellca lead the way in preclinical development. Through our robust platforms, off-the-shelf assays and commitment to providing a total solution, Sartorius Stedim Biotech can accelerate your drug’s development.

Biosimilar expertise

BioOutsource and Cellca have industry leading expertise in supporting biosimilar drug development. Collectively we have worked with over 50 biosimilar developers across 12 countries, totaling 230 biosimilar projects. Benefit from our combined experience and integrated services to further mitigate risks and select optimal biosimilar clones. Find out more.

Customers first

As a contract research organization, our service delivery and customer interaction are of the up most importance to us. Our service offering is underpinned by our commitment to delivering excellent customer service, navigating our customers through the complexities of the drug development cycle and enabling them to make informed data-driven decisions. Our client management team provide an intimate customer experience and ensure your project is managed efficiently and delivered on time. Effective communication is key to success, and our team understand that a transparent, proactive approach to customer service will ensure the delivery of a truly differentiated solution.

Contact our experts today to discuss your drug development programmes.


Sartorius Stedim Biotech Offers Services for Characterization of New Biological Entities (NBE)

Goettingen, GER | Glasgow, UK – January 23, 2019: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced the launch of services for new biological entities, called NBE Product Characterization. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced, industry-leading contract testing organization based in Glasgow, UK, and More

Sartorius Stedim BioOutsource win Frost & Sullivan Customer Service Leadership Award in Bioanlaytical Contract Testing Services

Goettingen, GER | Glasgow, UK, October 24, 2017 – Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, received the prestigious Frost & Sullivan’s 2017 European Customer Service Leadership Award for Bioanalytical Contract Testing Services. Presented at the Frost & Sullivan ceremony yesterday evening in London, UK, this award recognizes the unique More

Alligator Bioscience Select Sartorius Stedim Cellca as Cell Line Development Partner

Following the news release from Alligator Bioscience on 12th June 2017, Sartorius Stedim Cellca GmbH is delighted to partner with the innovative Swedish biotech company, Alligator Bioscience to support the pre-clinical development of their 4-1BB immuno-oncology antibody ATOR-1017. ATOR-1017 is an agonistic antibody that activates the co-stimulatory receptor 4-1BB (also known as CD137) expressed on More

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy